863 results on '"Desai, Jayesh"'
Search Results
202. Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy
203. CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research
204. Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
205. Abstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
206. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
207. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
208. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
209. Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).
210. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
211. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).
212. Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
213. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
214. CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
215. Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.
216. NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.
217. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia
218. A Malignant Neoplasm From the Jejunum With aMALAT1-GLI1Fusion and 26-Year Survival History
219. CD8 + tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival
220. Therapeutic strategies to remodel immunologically cold tumors
221. Rapid two-dimensional Protein-A size exclusion chromatography of monoclonal antibodies for titer and aggregation measurements from harvested cell culture fluid samples
222. Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood
223. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review
224. Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
225. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
226. Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management
227. Gemcitabine and Vinorelbine Combination Chemotherapy for Patients With Advanced Soft Tissue Sarcomas: Results of a phase II trial
228. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
229. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors
230. iPREDICT: Incorporating complex profiling of patients to enrol onto molecularly directed cancer therapeutics. Preliminary results of the adult and paediatric cohorts
231. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
232. Successive modifications of Folfox dose and schedule improves tolerability without compromising efficacy
233. A PHASE 1 AND PHARMACOKINETIC TRIAL OF OXALIPLATIN AND GEMCITABINE IN PATIENTS WITH SOLID TUMOURS: 2129
234. Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.
235. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology.
236. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours.
237. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
238. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
239. Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
240. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
241. Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study
242. Abstract 1472: Novel vaccine targeting colonic adenoma: A pre-clinical model
243. The value of networks in driving phase I trials: the Peter MacCallum Cancer Centre experience
244. Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.
245. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
246. Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.
247. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
248. PD47-01 BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER
249. BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).
250. A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.